France's Median Technologies Q3 revenue rises to record high

Overview

• France medical imaging firm's Q3 revenue rose 14.4% yr/yr to record €6.7 mln

• Order backlog hit record €90.9 mln at end-September, up 23.5% yr/yr

Outlook

• Company expects first eyonis LCS revenues in the first half of 2027

• Company says cash runway extends through H1 2028, with potential extension to H1 2029 if warrants exercised

Result Drivers

• LARGE PROJECT WIN - Co secured €8.4 mln global Phase III oncology imaging project, contributing to order backlog and revenue growth

• BIOPHARMA DEMAND - Sustained demand from biopharma clients drove iCRO business momentum and backlog growth

• CHINA GROWTH - Revenue growth in H1 2026 mainly driven by China, up 10% yr/yr and accounting for 39% of group revenue

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Median Technologies SA is €12.95, about 196.3% above its October 28 closing price of €4.37

Reuters Recommended Reads

• Oct 28 - Glaukos Q3 revenue jumps 58% on iDose TR, Epioxa launches, Corneal Health growth

• Oct 28 - Joinn Laboratories Q3 revenue rises on industry recovery

• Oct 27 - Healthcare data firm IQVIA Q3 revenue beats on strong bookings

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)